GeneDx Holdings Corporation (WGS) News

GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024 

STAMFORD, Conn., July 11, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved...

GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients

-- New integration to streamline access for health systems and improve provider and patient journeys using Epic...

GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients

STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved...

GeneDx to Participate in Upcoming Investor Conferences

STAMFORD, Conn., May 22, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved...

GeneDx Reports First Quarter 2024 Financial Results and Business Highlights

Reported first quarter 2024 revenue from continuing operations1 of $61.5M with 96% year-over-year growth of...

GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset

STAMFORD, Conn., April 23, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved...

GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024

STAMFORD, Conn., April 04, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved...

GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics

STAMFORD, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved...

Form 4 - Statement of changes in beneficial ownership of securities

GeneDx to Participate in 44th Annual Cowen Health Care Conference

STAMFORD, Conn., Feb. 26, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024

Reported fourth quarter 2023 revenue from continuing operations1 of $58.1M with more than 68% year-over-year...

GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024 

STAMFORD, Conn., Feb. 01, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved...

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

STAMFORD, Conn., Jan. 24, 2024 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes...